Table 4.

Common biological processes enriched in genes from the adalimumab-associated module.

Biological pathwaya	Genesb	P-value	FDR
Nucleotide metabolism*	70	2.41e-05	0.026
GP1b-IX-V activation signaling	10	0.0061	0.068
Interleukin-7 signaling	11	0.0071	0.068
Pyrimidine catabolism	12	0.0071	0.068
Regulation of signaling by CBL	18	0.011	0.068
Synthesis and interconversion of nucleotide di- and triphosphates	18	0.011	0.068
Tie2 signaling	18	0.011	0.068
Signaling by constitutively active EGFR	19	0.011	0.068
CD28 dependent PI3K/Akt signaling	21	0.013	0.068
Nephrin interactions	22	0.013	0.068
Pyrimidine metabolism	24	0.014	0.068
Interleukin receptor SHC signaling	28	0.017	0.072
CD28 co-stimulation	31	0.019	0.072
GPVI-mediated activation cascade	33	0.021	0.072
PI3K/AKT activation	37	0.022	0.072
PI3K events in ERBB4 signaling	38	0.023	0.072
GAB1 signalosome	39	0.023	0.072
Interleukin-2 signaling	42	0.025	0.072
PI3K events in ERBB2 signaling	44	0.026	0.072
Interleukin-3, 5 and GM-CSF signaling	46	0.028	0.072
Downstream TCR signaling	50	0.031	0.072
Mitochondrial protein import	52	0.031	0.072
Antigen activates BCR leading to second messengers' generation	53	0.032	0.072
PI-3K cascade	57	0.034	0.074
TCR signaling	67	0.041	0.081
PI3K cascade	70	0.042	0.081
Costimulation by the CD28 family	76	0.045	0.081
G alpha (12/13) signaling events	77	0.046	0.081
Signaling by SCF-KIT	79	0.047	0.081
IRS-mediated signaling	81	0.048	0.081
IRS-related events	81	0.048	0.081

FDR, false discovery rate.

^aBiological processes significantly enriched in the adalimumab-associated module (P < 0.05).

^bNumber of genes included in the indicated biological process. The complete list of genes can be found in Table S5.

^*Biological processes showing a significant enrichment after multiple testing correction (FDR < 0.05).